Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

1.960 -0.010 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,598,658
Open 1.990
Bid (Size) 1.970 (5)
Ask (Size) 1.980 (14)
Prev. Close 1.970
Today's Range 1.950 - 2.030
52wk Range 0.7000 - 3.400
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-32.88%
-32.88%
1 Month
-25.19%
-25.19%
3 Month
-16.95%
-16.95%
6 Month
-27.14%
-27.14%
1 Year
+36.11%
+36.11%

More News

Read More
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
Via Talk Markets
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
Via Benzinga
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Via Benzinga
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Via Benzinga
Exposures Product Safety
Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.